Are all cyclin-dependent kinases 4/6 inhibitors created equal?

The harnessing in clinical practice of cyclin-dependent kinases 4/6 inhibitors, namely palbociclib, ribociclib, and abemaciclib, has substantially changed the therapeutic approach for hormone receptor-positive metastatic breast cancer (BC). Phase II–III clinical trials evaluating the addition of these agents to standard endocrine therapy reported consistent improvements in response rates and progression-free survival as well as manageable toxicity profiles and excellent impact on patients’ quality of life. Hence, pivotal trials provided comparable results among different cyclin-dependent kinases 4/6 inhibitors, there is an increasing interest in finding substantial differences in order to implement their use in clinical practice. The aim of this paper is to summarize the current evidences raised from preclinical and clinical studies on cyclin-dependent kinases 4/6 inhibitors in BC, focusing on differences in terms of pharmacological properties, toxicity profile, and patients’ quality of life.

• Publication year

  2019

• Venue

  npj Breast Cancer

• Publication date

  2019-08-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41523-019-0121-yPMID 31482107PMCID 6715721
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

  2020cited by this paper
• Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

  2019cited by this paper
• Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer

  2019cited by this paper
• Cyclin-Dependent Kinase Inhibitor-Associated Thromboembolism.

  2019cited by this paper
• Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.

  2019cited by this paper
• Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

  2019cited by this paper
• MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

  2019cited by this paper
• Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

  2018cited by this paper
• Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

  2018cited by this paper
• miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense.

  2018cited by this paper
• Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy.

  2018cited by this paper
• Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.

  2018cited by this paper
• Abstract PD5-01: Final results of NeoMONARCH: A phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC)

  2018cited by this paper
• Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

  2018cited by this paper
• CDK4/6 inhibition in breast cancer: current practice and future directions

  2018cited by this paper
• 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

  2018cited by this paper
• CDK4/6 inhibitors as neoadjuvant treatment in breast cancer-what can we learn?

  2018cited by this paper
• Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

  2018cited by this paper
• Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2

  2018cited by this paper
• A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.

  2018cited by this paper
• Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3.

  2018cited by this paper
• Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer

  2018cited by this paper
• Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

  2018cited by this paper
• Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.

  2017cited by this paper
• Edoxaban for the Treatment of Cancer‐Associated Venous Thromboembolism

  2017cited by this paper
• NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

  2017cited by this paper
• Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18).

  2017cited by this paper
• CDK4/6 inhibition triggers anti-tumor immunity

  2017cited by this paper
• Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer.

  2017cited by this paper
• MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

  2017cited by this paper
• MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

  2017cited by this paper
• MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

  2017cited by this paper
• Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations

  2017cited by this paper
• Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value

  2017cited by this paper
• Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.

  2017cited by this paper
• 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

  2017cited by this paper
• Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis

  2017cited by this paper
• Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.

  2016cited by this paper
• Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

  2016cited by this paper
• Patient-reported outcomes in the evaluation of toxicity of anticancer treatments

  2016cited by this paper
• Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

  2016cited by this paper
• Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.

  2016cited by this paper
• Treating cancer with selective CDK4/6 inhibitors

  2016cited by this paper
• Palbociclib and Letrozole in Advanced Breast Cancer.

  2016cited by this paper
• A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

  2016cited by this paper
• Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

  2016cited by this paper
• Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).

  2016cited by this paper
• Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

  2016cited by this paper
• Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

  2016cited by this paper
• Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

  2015cited by this paper
• The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

  2015cited by this paper
• Challenges in the management of advanced, ER-positive, HER2-negative breast cancer

  2015cited by this paper
• Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer.

  2015cited by this paper
• Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

  2015cited by this paper
• Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

  2014cited by this paper
• CDK9 inhibition strategy defines distinct sets of target genes

  2014cited by this paper
• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

  2014cited by this paper
• Abstract CT232: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer

  2014cited by this paper
• Abstract 4756: In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer

  2014cited by this paper
• Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.

  2013cited by this paper
• Cancer Genome Landscapes

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.

  2011cited by this paper
• Phase I Study of PD 0332991, a Novel, Oral, Cyclin-D Kinase (CDK) 4/6 Inhibitor in Combination with Letrozole, for First-Line Treatment of Metastatic Post-Menopausal, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer.

  2009cited by this paper
• PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

  2009cited by this paper
• Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer

  2009cited by this paper
• Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

  2004cited by this paper
• Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.

  1999cited by this paper
• Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4

  1997cited by this paper
• Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.

  1994cited by this paper

• CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis

  2026cites this paper
• Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2–Negative Metastatic Breast Cancer

  2025cites this paper
• A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer

  2025cites this paper
• CDK4/6 Inhibitor Resistance in ER+ Breast Cancer.

  2025cites this paper
• Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial

  2025cites this paper
• Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences

  2025cites this paper
• Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis

  2025cites this paper
• Cardiovascular toxicity of cyclin-dependent kinase 4 and 6 inhibitors

  2025cites this paper
• The promise of ctDNA-based, molecularly-driven early switch therapy from PADA-1 to SERENA-6

  2025cites this paper
• Heteroleptic N, N donor carbonitrile based Au(III) complexes: DNA/BSA interaction studies, Molecular Docking, and cytotoxicity studies.

  2025cites this paper
• Serum Proteomics of Ribociclib‐Mediated Cardiovascular Toxicity: An Exploratory Case–Control Study

  2025cites this paper
• Advances in breast cancer therapy: "Exploring the therapeutic potential of CDK 4/6 inhibitors and their clinical impact."

  2025cites this paper
• Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells

  2025cites this paper
• Current progress in targeting mitotic kinases in PDAC.

  2025cites this paper
• Novel Small Molecule Inhibitors of Cyclin-dependent Kinases as Anticancer Agents.

  2025cites this paper
• Development and validation of an LC-MS/MS method for simultaneous determination of XZP-3287(bireociclib) and its metabolites in human plasma, and its clinical pharmacokinetics application.

  2025cites this paper
• Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives

  2024cites this paper
• Continuation of CDK4/6 Inhibition and Switching of Hormonal Therapy After Progression on Prior CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis

  2024cites this paper
• Development of novel CDK9 and CYP3A4 inhibitors for cancer therapy through field and computational approaches

  2024influential citation
• In silico identification of novel CDK4 inhibitors for retinoblastoma.

  2024cites this paper
• First‑line endocrine therapy for hormone receptor positive and HER‑2 negative metastatic breast cancer: A Bayesian network meta‑analysis

  2024cites this paper
• Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer

  2024cites this paper
• CDK4/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment in Rb-deficient small cell lung cancer

  2024cites this paper
• Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review

  2024cites this paper
• Hematological toxicity of cyclin-dependent kinase 4/6 inhibitors in patients with breast cancer: a network meta-analysis and pharmacovigilance study

  2024cites this paper
• CDK4/6 inhibitors: The Devil is in the Detail

  2024cites this paper
• Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study

  2024cites this paper
• A systematic review on understanding the mechanistic pathways and clinical aspects of natural CDK inhibitors on cancer progression.: Unlocking cellular and biochemical mechanisms.

  2024cites this paper
• Unveiling novel therapeutic avenues: Targeting the cyclin D/CDK4 axis for enhanced cancer treatment

  2024cites this paper
• Cardiovascular complications of ribociclib in breast cancer patients.

  2024cites this paper
• Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review).

  2024cites this paper
• Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending

  2024cites this paper
• Seize the engine: Emerging cell cycle targets in breast cancer

  2024cites this paper
• The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials

  2024cites this paper
• Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2− breast cancer: an umbrella review

  2024influential citation
• Palbociclib: efficacy and safety in older patients

  2023cites this paper
• Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer.

  2023cites this paper
• Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors

  2023cites this paper
• Enhancing immunogenic responses through CDK4/6 and HIF2α inhibition in Merkel cell carcinoma

  2023cites this paper
• Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients

  2023cites this paper
• Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers

  2023cites this paper
• The CDK4/6 Inhibitors Biomarker Landscape: the most Relevant Biomarkers of Response or Resistance for Further Research and Potential Clinical Utility.

  2023cites this paper
• p21 prevents the exhaustion of CD4+ T cells within the antitumor immune response against colorectal cancer.

  2023cites this paper
• Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer

  2023cites this paper
• Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling

  2023cites this paper
• Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer

  2023cites this paper
• Hair loss during and after breast cancer therapy

  2023cites this paper
• The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer

  2023cites this paper
• Mathematically Modeling the Effect of Endocrine and Cdk4/6 Inhibitor Therapies on Breast Cancer Cells.

  2023cites this paper
• A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression

  2023cites this paper
• Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.

  2023cites this paper
• Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib

  2023cites this paper
• Efficacy and safety of cyclin‐dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real‐world experience

  2023cites this paper
• Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: a personalized approach.

  2022cites this paper
• Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase

  2022cites this paper
• Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges

  2022cites this paper
• Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?

  2022cites this paper
• Advances in therapeutic agents targeting quiescent cancer cells

  2022cites this paper
• Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment

  2022cites this paper
• Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside

  2022cites this paper
• Functional genomic analysis of CDK4 and CDK6 gene dependency across human cancer cell lines.

  2022cites this paper
• Stable H-bond networks are crucial for selective CDK4 inhibition revealed from comprehensive in silico investigation

  2022cites this paper
• In vivo visualization of fluorescence reflecting CDK4 activity in a breast cancer mouse model

  2022cites this paper
• Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity

  2022influential citation
• Targeting ESR1 mutation–induced transcriptional addiction in breast cancer with BET inhibition

  2022cites this paper
• CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin–proteasome pathway in ER + breast cancer

  2022cites this paper
• Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib

  2022cites this paper
• CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials

  2022influential citation
• The Combination of CDK 4/6 Inhibitors plus Endocrine Treatment versus Endocrine Treatment Alone in Hormone-receptor (HR)-Positive breast Cancer: a Systematic Review and Meta-analysis

  2022cites this paper
• ‘Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research’

  2022cites this paper
• CDK4/6 inhibitor plus endocrine therapy for hormone receptor‐positive, HER2‐negative metastatic breast cancer: The new standard of care

  2021cites this paper
• Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials

  2021cites this paper
• Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.

  2021cites this paper
• Palbociclib as an early-line treatment for Japanese patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: a review of clinical trial and real-world data

  2021cites this paper
• Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis.

  2021cites this paper
• Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

  2021cites this paper
• The role of CDK4/6 inhibitors in early breast cancer

  2021cites this paper
• Adjuvant cyclin‐dependent kinase 4/6 inhibition in hormone receptor–positive breast cancer: One Monarch to rule them all?

  2021cites this paper
• Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer

  2021cites this paper
• Gold Derivatives Development as Prospective Anticancer Drugs for Breast Cancer Treatment

  2021cites this paper
• AMPK Is the Crucial Target for the CDK4/6 Inhibitors Mediated Therapeutic Responses in PANC-1 and MIA PaCa-2 Pancreatic Cancer Cell Lines

  2021cites this paper
• Inhibition of CDK4/6 kinases causes production of aneuploid oocytes by inactivating the spindle assembly checkpoint and accelerating first meiotic progression.

  2021cites this paper
• Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action

  2021cites this paper
• CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis

  2021cites this paper
• Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer

  2021cites this paper
• CDK4/6 inhibitors induce replication stress to cause long‐term cell cycle withdrawal

  2021cites this paper
• A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients

  2020cites this paper
• Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives

  2020cites this paper
• Actualidades en el manejo sistémico del cáncer de mama

  2020cites this paper
• Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer

  2020cites this paper
• Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets

  2020cites this paper
• The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC)

  2020influential citation
• A UNIQUE CDK4/6 INHIBITOR: CURRENT AND FUTURE THERAPEUTIC STRATEGIES OF ABEMACICLIB.

  2020cites this paper
• Updates on the treatment of invasive breast cancer: Quo Vadimus?

  2020cites this paper
• Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)

  2020cites this paper
• Genome-wide CRISPR and small-molecule screens uncover targetable dependencies in ATRT

  2020influential citation
• Targeting mutated estrogen receptor alpha: Rediscovering old and identifying new therapeutic strategies in metastatic breast cancer treatment

  2020cites this paper
• CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?

  2020cites this paper
• Characterization of the Synergistic Inhibition of IK(erg) and IK(DR) by Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor

  2020cites this paper
• Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers

  2020cites this paper